133
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          To develop expert consensus on a suite of reporting standards for HRQL outcomes of RCTs.

          Methods

          A Task Force of The International Society of Quality of Life Research (ISOQOL) undertook a systematic review of the literature to identify candidate reporting standards for HRQL in RCTs. Subsequently, a web-based survey was circulated to the ISOQOL membership. Respondents were asked to rate candidate standards on a 4-point Likert scale based on their perceived value in reporting studies in which HRQL was a study outcome (primary or secondary). Results were synthesized into draft reporting guidelines, which were further reviewed by the membership to inform the final guidance.

          Results

          Forty-six existing candidate standards for reporting HRQL results in RCTs were synthesized to produce a 40 item survey that was completed electronically by 161 respondents. The majority of respondents rated all 40 items to be either ‘essential’ or ‘desirable’ when HRQL was a primary RCT outcome. Ratings changed when HRQL was a secondary study outcome. Feedback on the survey findings resulted in the Task Force generalizing the guidance to include patient-reported outcomes (PROs). The final guidance, which recommends standards for use in reporting PROs generally, and more specifically, for PROs identified as primary study outcomes, was approved by the ISOQOL Board of Directors.

          Conclusions

          ISOQOL has developed a suite of recommended standards for reporting PRO results of RCTs. Improved reporting of PROs will enable accurate interpretation of evidence to inform patient choice, aid clinical decision making, and inform health policy.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.

          The CONSORT (Consolidated Standards of Reporting Trials) statement is used worldwide to improve the reporting of randomized, controlled trials. Schulz and colleagues describe the latest version, CONSORT 2010, which updates the reporting guideline based on new methodological evidence and accumulating experience.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Recommendations on health-related quality of life research to support labeling and promotional claims in the United States.

            Health-related quality of life (HRQL) outcomes evaluation is becoming an important component of clinical trials of new pharmaceuticals and medical devices. HRQL research provides patients, providers, and decision makers with important information on the impact of disease and treatment on physical, psychological, and social functioning and well-being. These outcomes are also useful to the pharmaceutical and device industries as they attempt to understand and communicate product value to physicians, patients, health insurers and others. HRQL labeling and promotional claims in the US are likely to increase over the next few years. The evidentiary requirements to make such a claim should be based on accepted scientific standards of HRQL evaluation and consistent with the regulatory requirements for clinical efficacy. This report outlines the scientific practices that should be considered in the evaluation of evidence for an HRQL claim, including the selection of appropriate domains, evidence to support the reliability and validity of HRQL measurement, considerations in research design and statistical analyses, and the issue of clinical significance. Representatives from the pharmaceutical and device industries, regulatory agencies, and the HRQL scientific community should work together to make certain the use of HRQL in labeling and promotion are based on sound scientific evidence, and that these messages are clearly and accurately reported to the consumers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Patient-reported outcomes in cancer: a review of recent research and policy initiatives.

              There is growing recognition that patient-reported outcome (PRO) measures--encompassing, for example, health-related quality of life--can complement traditional biomedical outcome measures (eg, survival, disease-free survival) in conveying important information for cancer care decision making. This paper provides an integrated review and interpretation of how PROs have been defined, measured, and used in a range of recent cancer research and policy initiatives. We focus, in turn, on the role of PRO measurement in the evaluation and approval of cancer therapies, the assessment of cancer care in the community, patient-provider decision making in clinical oncology practice, and population surveillance of cancer patients and survivors. The paper concludes with a discussion of future challenges and opportunities in PRO measure development and application, given the advancing state of the science in cancer outcomes measurement and the evolving needs of cancer decision makers at all levels.
                Bookmark

                Author and article information

                Contributors
                m.calvert.1@bham.ac.uk
                Journal
                Qual Life Res
                Qual Life Res
                Quality of Life Research
                Springer Netherlands (Dordrecht )
                0962-9343
                1573-2649
                18 September 2012
                18 September 2012
                2013
                : 22
                : 6
                : 1161-1175
                Affiliations
                [ ]Queen’s University, Kingston, ON Canada
                [ ]MRC ConDuCT Hub for Trials Methodology Research, School of Social and Community Medicine, University of Bristol, Bristol, UK
                [ ]Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD USA
                [ ]Department of Epidemiology and Biostatistics, EMGO- Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands
                [ ]MRC Midland Hub for Trials Methodology Research, School of Health and Population Sciences, University of Birmingham, Birmingham, UK
                [ ]Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center, Rome, Italy
                [ ]Psycho-oncology Co-operative Research Group (PoCoG), University of Sydney, Sydney, Australia
                [ ]Department of Family Medicine and Primary Care, University of Hong Kong, Pokfulam, Hong Kong
                [ ]Ottawa Hospital Research Institute, Ottawa, Canada
                [ ]PRO Center of Excellence, Global Commercial Strategy Organization, Jansen Global Services, Warrington, UK
                [ ]Mayo Clinic Cancer Center, Rochester, MN USA
                [ ]Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, MD USA
                [ ]Northwestern University Feinberg School of Medicine, Chicago, IL USA
                Article
                252
                10.1007/s11136-012-0252-1
                3731511
                22987144
                25227a95-b6cf-4968-9647-608fb76a69f7
                © The Author(s) 2012
                History
                : 6 August 2012
                Categories
                Article
                Custom metadata
                © Springer Science+Business Media Dordrecht 2012

                Public health
                reporting,randomized clinical trials,quality of life,patient-reported outcomes,guidelines

                Comments

                Comment on this article